Literature DB >> 23231660

Triggering receptor expressed on myeloid cells-1 and 2 in bronchoalveolar lavage fluid in pulmonary sarcoidosis.

Magda Suchankova1, Maria Bucova, Elena Tibenska, Eva Tedlova, Juraj Demian, Ivan Majer, Helena Novosadova, Miroslav Tedla, Ema Paulovicova, Daniela Kantarova.   

Abstract

BACKGROUND AND
OBJECTIVE: Pulmonary sarcoidosis (PS) is characterized by the formation of granulomas in the lungs and has been associated with infection by microorganisms. Triggering receptor expressed on the surface of myeloid cells (TREM)-1 is overexpressed in response to infection while TREM-2 is involved in granuloma formation. We hypothesized that these receptors are overexpressed in PS and might be useful for diagnostic testing.
METHODS: Cell surface TREM-1 and TREM-2 expression in cells obtained at bronchoalveolar lavage (BAL) was measured in individuals with sarcoidosis (n = 26) and compared with that seen in individuals with other interstitial lung diseases (ILD) (n = 27).
RESULTS: TREM-1 and TREM-2 expression was significantly increased in sarcoidosis compared with other ILD: total number of TREM-1, P = 0.0039 (23.81 vs 13.50 cells/μl), TREM-2, P < 0.0001 (32.81 vs 7.76 cells/μl); percentage of TREM-1: P = 0.0002 (41.30% vs 15.70%), TREM-2: P < 0.0001 (34% vs 9.60%); and mean fluorescence of TREM-1: P = 0.0005 (5.43 vs 1.96), TREM-2: P = 0.0011 (6.85 vs 2.77). Increase in both of these receptors seems to be typical for PS. In discriminating sarcoidosis from other ILD, the specificity (96%) and sensitivity (72%) of the combination of TREM-1 and TREM-2 was high.
CONCLUSIONS: Increased TREM-1 and TREM-2 cell surface expression is observed in sarcoidosis. Evaluation of BAL cell expression of both of these receptors may serve as a diagnostic marker for sarcoidosis.
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23231660     DOI: 10.1111/resp.12028

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  7 in total

1.  High mobility group box 1 protein in bronchoalveolar lavage fluid and correlation with other inflammatory markers in pulmonary diseases.

Authors:  Magda Suchankova; Vladimira Durmanova; Elena Tibenska; Eva Tedlova; Ivan Majer; Helena Novosadova; Juraj Demian; Miroslav Tedla; Maria Bucova
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  TREM-2 Receptor Expression Increases with 25(OH)D Vitamin Serum Levels in Patients with Pulmonary Sarcoidosis.

Authors:  Maria Bucova; Magda Suchankova; Elena Tibenska; Eva Tedlova; Juraj Demian; Ivan Majer; Helena Novosadova; Miroslav Tedla
Journal:  Mediators Inflamm       Date:  2015-06-16       Impact factor: 4.711

3.  Diagnostic Performance of Bronchoalveolar Lavage Fluid CD4/CD8 Ratio for Sarcoidosis: A Meta-analysis.

Authors:  Yongchun Shen; Caishuang Pang; Yanqiu Wu; Diandian Li; Chun Wan; Zenglin Liao; Ting Yang; Lei Chen; Fuqiang Wen
Journal:  EBioMedicine       Date:  2016-04-21       Impact factor: 8.143

4.  Increased TREM-2 expression on the subsets of CD11c+ cells in the lungs and lymph nodes during allergic airway inflammation.

Authors:  Sannette C Hall; Devendra K Agrawal
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

5.  TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients.

Authors:  K Kluckova; J Kozak; K Szaboova; B Rychly; M Svajdler; M Suchankova; E Tibenska; B Filova; J Steno; V Matejcik; M Homolova; M Bucova
Journal:  Mediators Inflamm       Date:  2020-07-01       Impact factor: 4.711

6.  Inhibition of TREM-2 Markedly Suppresses Joint Inflammation and Damage in Experimental Arthritis.

Authors:  Alexander B Sigalov
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

Review 7.  Year in review 2013: Acute lung injury, interstitial lung diseases, sleep and physiology.

Authors:  Amanda Piper; Yuanlin Song; Neil D Eves; Toby M Maher
Journal:  Respirology       Date:  2014-02-21       Impact factor: 6.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.